Association of Pharmacologic and Nonpharmacologic Management
of Acute Low Back Pain with Overdose Hospitalizations:
A Nested Case-Control Study

This section is compiled by Frank M. Painter, D.C.
Send all comments or additions to:    Frankp@chiro.org

FROM:   J Integrative and Complementary Medicine 2025 (Apr 3); ~ FULL TEXT

OPEN ACCESS

---

Patience M Dow • Neto Coulibaly • Anthony Girard • Jessica S Merlin • Theresa I Shireman
Amal N Trivedi • Richa Gairola • Brandon D L Marshall

Department of Health Services, Policy, and Practice,
Brown University School of Public Health,
Providence, Rhode Island, USA.

---

---

Background:   Noninvasive nonpharmacologic therapies are recommended for managing acute low back pain (aLBP) and have the potential to mitigate opioid-related harms. However, little is known about whether incorporating nonpharmacologic therapies into aLBP management affects adverse outcomes. The objective was to determine if receiving nonpharmacologic pain therapies, alone or combined with pharmacologic options, is associated with drug-related overdose hospitalizations among Medicare beneficiaries with aLBP.

Methods:   A nested case-control study was conducted using 2016-2019 Medicare claims to identify fee-for-service beneficiaries with new episodes of aLBP (i.e., LBP lasting <3 months). Cases had inpatient claims for drug overdoses within 90 days of aLBP diagnosis.

The exposure was mutually exclusive categories for pain therapies:

(1)   pharmacologic only (opioids and/or gabapentinoids),

(2)   nonpharmacologic only (physical therapy and/or spinal manipulation therapy),

(3)   both pharmacologic and nonpharmacologic, and

(4) none of these.

The outcome was hospitalization involving drug overdose. We conducted conditional logistic regression adjusting for baseline sociodemographic, clinical, and geographic covariates.

Results:   There were 3,042 cases and 12,168 matched controls. One-third (33.7%) of cases versus 26.8% of controls received pharmacologic therapies only compared with 6.7% (cases) and 10.2% (controls) for nonpharmacologic therapies only. Receipt of both pharmacologic and nonpharmacologic therapies was 7.3% (cases) and 3.2% (controls). Compared with exclusively receiving pharmacologic therapies, receiving nonpharmacologic therapies only was associated with lower odds of overdose-related hospitalization (adjusted odds ratio [aOR] = 0.56, 95% confidence interval [CI]: 0.47-0.66), whereas pharmacologic and nonpharmacologic treatments combined were associated with nearly twofold increased odds of overdose-related hospitalization (aOR = 1.87, 95% CI: 1.55-2.27).

Conclusions:   Among Medicare beneficiaries with new episodes of aLBP, treatment with only nonpharmacologic therapies was protective of overdose hospitalizations. However, any treatment with opioids and/or gabapentinoids, alone or combined with nonpharmacologic therapies, was associated with increased odds of overdose hospitalization. Implementation research is needed to inform successful adoption of nonpharmacologic pain therapies especially in subgroups with increased risk of adverse outcomes.

Keywords:   Medicare; acute pain; gabapentin; opioid prescribing; physical therapy; spinal manipulation therapy.

---

References:

1. Oertel J, Sharif S, Zygourakis C, et al.
   Acute low back pain: Epidemiology, etiology, and prevention:
   WFNS spine committee recommendations.
   World Neurosurg X 2024;22:100313;

2. Urits I, Burshtein A, Sharma M, et al.
   Low back pain, a comprehensive review:
   Pathophysiology, diagnosis, and treatment.
   Curr Pain Headache Rep 2019;23(3):23;

3. Goodman CW, Brett AS.
   Gabapentin and pregabalin for pain—
   is increased prescribing a cause for concern?
   N Engl J Med 2017;377(5):411–414;

4. Deyo RA, Von Korff M, Duhrkoop D.
   Opioids for low back pain.
   BMJ 2015;350(jan05 10):g6380;

5. Pauly NJ, Delcher C, Slavova S, et al.
   Trends in gabapentin prescribing in a commercially insured
   U.S. adult population, 2009-2016.
   J Manag Care Spec Pharm 2020;26(3):246–252;

6. Johansen ME.
   Gabapentinoid use in the United States 2002 through 2015.
   JAMA Intern Med 2018;178(2):292–294;

7. Lakkad M, Martin B, Li C, et al.
   The use of gabapentinoids and opioids and risk of developing
   opioid-induced respiratory depression among older
   breast cancer survivors with neuropathic pain.
   J Cancer Surviv 2024;18(3):917–927;

8. Humpert SR, Reveles KR, Bhakta K, et al.
   Association of gabapentinoids with opioid-related overdose in the
   inpatient setting: A single center retrospective case-control study.
   Hosp Pharm 2024;59(2):188–197;

9. Chen C, Lo-Ciganic W-H, Winterstein AG, et al.
   Concurrent use of prescription opioids and gabapentinoids in older adults.
   Am J Prev Med 2022;62(4):519–528;

10. Zhou L, Bhattacharjee S, Kwoh CK, et al.
    Dual-trajectories of opioid and gabapentinoid use and risk of subsequent
    drug overdose among Medicare beneficiaries in the United States:
    A retrospective cohort study.
    Addiction 2021;116(4):819–830;

11. Dowell D, Ragan KR, Jones CM, et al.
    CDC clinical practice guideline for prescribing opioids
    for pain—United States, 2022.
    MMWR Recomm Rep 2022;71(3):1–95;

12. Qaseem A, Wilt TJ, McLean RM, et al.;
    Noninvasive Treatments for Acute, Subacute, and Chronic
    Low Back Pain: A Clinical Practice Guideline From
    the American College of Physicians
    Annals of Internal Medicine 2017 (Apr 4); 166 (7): 514–530

13. Casazza BA.
    Diagnosis and treatment of acute low back pain.
    Am Fam Physician 2012;85(4):343–350.
    https://www.aafp.org/pubs/afp/issues/2012/0215/p343.html

14. Sanger N, Bhatt M, Singhal N, et al.
    Adverse outcomes associated with prescription opioids for
    acute low back pain: A systematic review and meta-analysis.
    Pain Physician 2019;22(2):119–138. https://.ncbi.nlm.nih.gov/30921976/

15. Chou R, Huffman LH, American College of Physicians.
    Nonpharmacologic Therapies for Acute and Chronic Low Back Pain:
    A Review of the Evidence for an American Pain Society/American
    College of Physicians Clinical Practice Guideline
    Annals of Internal Medicine 2007 (Oct 2); 147 (7): 492–504

16. Jones CMP, Day RO, Koes BW, et al.;
    OPAL Investigators Coordinators.
    Opioid analgesia for acute low back pain and neck pain.
    Lancet 2023;402(10398):304–312;

17. Su X, Qian H, Chen B, et al.
    Acupuncture for acute low back pain:
    A systematic review and meta-analysis.
    Ann Palliat Med 2021;10(4):3924–3936;

18. Brintz CE, Cheatle MD, Dember LM, et al.;
    HOPE Consortium. Nonpharmacologic treatments for opioid
    reduction in patients with advanced chronic kidney disease.
    Semin Nephrol 2021;41(1):68–81;

19. Chou R, Turner JA, Devine EB, et al.
    The effectiveness and risks of long-term opioid therapy for chronic pain:
    A systematic review for a national institutes of
    health pathways to prevention workshop.
    Ann Intern Med 2015;162(4):276–286;

20. Krebs EE, Gravely A, Nugent S, et al.
    Effect of opioid vs nonopioid medications on pain-related function in
    patients with chronic back pain or hip or knee osteoarthritis pain:
    The SPACE randomized clinical trial.
    JAMA 2018;319(9):872–882;

21. Sun E, Moshfegh J, Rishel CA, et al.
    Association of early physical therapy with long-term opioid
    use among opioid-naive patients with musculoskeletal pain.
    JAMA Netw Open 2018;1(8):e185909;

22. Banta-Green CJ, Coffin PO, Merrill JO, et al.
    Impacts of an opioid overdose prevention intervention
    delivered subsequent to acute care.
    Inj Prev 2019;25(3):191–198;

23. Song Z.
    Mortality quadrupled among opioid-driven hospitalizations,
    notably within lower-income and disabled white populations.
    Health Aff (Millwood) 2017;36(12):2054–2061;

24. Heer HD, Warren M.
    Physical therapy and hospitalization among medicare beneficiaries
    with low back pain: A retrospective cohort study.
    Spine (Phila Pa 1976)) 2016;41(19):1515–1522;

25. Kuo YF, Baillargeon J, Raji MA.
    Overdose deaths from nonprescribed prescription opioids, heroin,
    and other synthetic opioids in Medicare beneficiaries.
    J Subst Abuse Treat 2021;124:108282;

26. Shoff C, Yang TC, Shaw BA.
    Trends in opioid use disorder among older adults:
    Analyzing medicare data, 2013–2018.
    Am J Prev Med 2021;60(6):850–855;

27. Mikosz CA, Zhang K, Haegerich T, et al.
    Indication-specific opioid prescribing for US patients
    with medicaid or private insurance, 2017.
    JAMA Netw Open 2020;3(5):e204514;

28. Lo-Ciganic WH, Huang JL, Zhang HH, et al.
    Evaluation of machine-learning algorithms for predicting opioid overdose
    risk among medicare beneficiaries with opioid prescriptions.
    JAMA Netw Open 2019;2(3):e190968;

29. Compton WM, Valentino RJ, DuPont RL.
    Polysubstance use in the U.S. opioid crisis.
    Mol Psychiatry 2021;26(1):41–50;

30. Gagne JJ, Glynn RJ, Avorn J, et al.
    A combined comorbidity score predicted mortality in
    elderly patients better than existing scores.
    J Clin Epidemiol 2011;64(7):749–759;

31. Centers for Disease Control and Prevention.
    Opioid National Drug Code and Oral MME Conversion File update.
    Available from: ttps://archive.cdc.gov/www_cdc_gov/opioids/
    data-resources/index.html
    [Last accessed: February 1, 2023].

32. Dowell D, Haegerich TM, Chou R.
    CDC guideline for prescribing opioids for chronic pain—United States, 2016.
    JAMA 2016;315(15):1624–1645;

33. Matheson C, Vucic C, Dumbrell J, et al.
    Clinical outcomes of benzodiazepine prescribing for people receiving
    opioid agonist treatment: A systematic review of the evidence.
    Pharmacy (Basel) 2024;12(5);

34. Bise CG, Schneider M, Freburger J, et al.
    First provider seen for an acute episode of low back pain
    influences subsequent health care utilization.
    Phys Ther 2023;103(9);

35. Elton D, Zhang M.
    Low back pain care pathways – is the last provider seen more
    important than the first: A retrospective cohort study.
    medRxiv 2022;

36. Fritz JM, Kim J, Dorius J.
    Importance of the Type of Provider Seen to Begin Health Care for a New
    Episode Low Back Pain: Associations with Future Utilization and Costs
    J Eval Clin Pract. 2016 (Apr); 22 (2): 247–252

37. Rhee Y, Taitel MS, Walker DR, et al.
    Narcotic drug use among patients with lower back pain in employer
    health plans: A retrospective analysis of risk factors
    and health care services.
    Clin Ther 2007;29(Suppl):2603–2612;

38. Whedon JM, Toler AWJ, Goehl JM, et al.
    Association Between Utilization of Chiropractic Services for
    Treatment of Low-Back Pain and Use of Prescription Opioids
    J Manipulative Physiol Ther 2018 (Jun); 41 (5): 383–388

39. Luca K, McLachlan AJ, Maher CG, et al.
    Australian emergency department care for older adults diagnosed with
    low back pain of lumbar spine origin: A retrospective analysis
    of electronic medical record system data (2016–2019).
    BMC Emerg Med 2023;23(1):67;

40. Vogt MT, Kwoh CK, Cope DK, et al.
    Analgesic usage for low back pain:
    Impact on health care costs and service use.
    Spine (Phila Pa 1976)) 2005;30(9):1075–1081;

41. Whedon JM, Kizhakkeveettil A, Toler AWJ, et al.
    Initial Choice of Spinal Manipulation Reduces
    Escalation of Care for Chronic Low Back Pain
    Among Older Medicare Beneficiaries.
    Spine (Phila Pa 1976) 2022 (Feb 15); 47 (4): E142–E148

42. Trager RJ, Cupler ZA, Srinivasan R, et al.
    Association Between Chiropractic Spinal Manipulation
    for Sciatica and Opioid-related Adverse Events:
    A Retrospective Cohort Study
    PLoS One 2025 (Jan 28); 20 (1): e0317663

43. Binswanger IA, Glanz JM, Faul M, et al.
    The association between opioid discontinuation and heroin use:
    A nested case-control study.
    Drug Alcohol Depend 2020;217:108248;

44. Kennedy MC, Crabtree A, Nolan S, et al.
    Discontinuation and tapering of prescribed opioids and risk of overdose
    among people on long-term opioid therapy for pain with and without
    opioid use disorder in British Columbia, Canada:
    A retrospective cohort study.
    PLoS Med 2022;19(12):e1004123;

45. Coffin PO, Rowe C, Oman N, et al.
    Illicit opioid use following changes in opioids
    prescribed for chronic non-cancer pain.
    PLoS One 2020;15(5):e0232538;

46. George SZ, Lentz TA, Goertz CM.
    Back and Neck Pain: In Support of Routine Delivery of
    Non-pharmacologic Treatments as a way to Improve
    Individual and Population Health
    Translational Research 2021 (Apr 24); S1931-5244 (21) 00088-8

47. Heyward J, Jones CM, Compton WM, et al.
    Coverage of Nonpharmacologic Treatments for Low Back Pain
    Among US Public and Private Insurers
    JAMA Network Open 2018 (Oct 5); 1 (6): e183044

48. Gray M, Cooke A, Livingston CJ, et al.
    “It has improved my practice to be able to offer alternative treatments”:
    A longitudinal qualitative study of oregon medicaid back pain providers.
    J Integr Complement Med 2024;30(11):1092–1101;

49. Kazis LE, Ameli O, Rothendler J, et al.
    Observational Retrospective Study of the Association of
    Initial Healthcare Provider for New-onset Low Back
    Pain with Early and Long-term Opioid Use
    BMJ Open. 2019 (Sep 20); 9 (9): e028633

50. Lin DH, Jones CM, Compton WM, et al.
    Prescription drug coverage for treatment of low back pain
    among US medicaid, medicare advantage, and commercial insurers.
    JAMA Netw Open 2018;1(2):e180235;

Return to OPIOID EPIDEMIC

Return to the MEDICARE Page

Return NON-PHARMACOLOGIC THERAPY

Since 4-06-2025